Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

Phase 3positiveTrastuzumab BotidotinT-DM1Positive

AI Analysis

Summary

Sichuan Kelun-Biotech announced Phase III registrational study results of Trastuzumab Botidotin versus T-DM1 in HER2-positive breast cancer published in the Journal of Clinical Oncology.

Clinical Trial Data

Phase

Phase III

Outcome Details

Phase III registrational study results published in JCO

Importance:7/10

Sentiment:

0.70

Phase IIIHER2-positive breast cancerantibody-drug conjugateregistrational studypublished results

Related Companies

$SKBBY

Read the original article

Published by PR Newswire Pharma on September 14, 2026 6:18 AM

Read Original